• HARPER BAZAAR x CARTIER - Cover June 2024

    Creative Director: Trần Đạt.
    Photographer: Huỳnh Trí Nghĩa
    Producer: Duyên Nguyễn
    Stylist: #D2Styling Phương Nam
    Makeup: Dương Hữu Nghĩa.
    Hair: Nhất Linh
    HARPER BAZAAR x CARTIER - Cover June 2024 Creative Director: Trần Đạt. Photographer: Huỳnh Trí Nghĩa Producer: Duyên Nguyễn Stylist: #D2Styling Phương Nam Makeup: Dương Hữu Nghĩa. Hair: Nhất Linh
    Like
    Love
    Wow
    3
    · 0 Comments ·0 Shares ·46K Views
  • In June 2025, the U.S. Food and Drug Administration (FDA) officially approved Yeztugo (lenacapavir) as the world’s first twice-yearly injection for HIV prevention (PrEP).

    Developed by Gilead Sciences, this landmark drug offers long-term protection from HIV with just two subcutaneous shots per year.

    The approval is based on extensive clinical trials under the PURPOSE 1 and 2 studies, which showed near-perfect efficacy—zero new infections in cisgender women and only two infections across a broader population of over 2,000 individuals.

    This brings its protective rate to approximately 99.9%, making it the most effective and long-acting HIV prevention method available today.

    Lenacapavir works by targeting the HIV capsid, a protein shell that encases the virus’s genetic material.

    By inhibiting this capsid, the drug prevents HIV from replicating inside human cells.

    Unlike daily oral PrEP options like Truvada or Descovy, Yeztugo is designed to overcome common adherence issues by requiring just one injection every six months. This simplifies prevention for at-risk

    populations, especially those who struggle with daily medication routines.

    While the approval is being hailed as a major victory in the global fight against HIV, access and affordability remain concerns.

    The U.S. list price for a year’s supply is expected to be around $28,000, though Gilead has committed to providing generics to 120 low-income countries and producing up to 10 million doses by 2026.

    Global health experts see this breakthrough as a turning point that could drastically reduce new HIV infections—if distribution is equitable and timely.

    In summary, Yeztugo's approval represents a critical milestone in HIV prevention science, combining exceptional efficacy, convenience, and innovation.

    It has the potential to reshape the future of HIV prevention—especially if healthcare systems can ensure widespread access to those most in need.
    In June 2025, the U.S. Food and Drug Administration (FDA) officially approved Yeztugo (lenacapavir) as the world’s first twice-yearly injection for HIV prevention (PrEP). Developed by Gilead Sciences, this landmark drug offers long-term protection from HIV with just two subcutaneous shots per year. The approval is based on extensive clinical trials under the PURPOSE 1 and 2 studies, which showed near-perfect efficacy—zero new infections in cisgender women and only two infections across a broader population of over 2,000 individuals. This brings its protective rate to approximately 99.9%, making it the most effective and long-acting HIV prevention method available today. Lenacapavir works by targeting the HIV capsid, a protein shell that encases the virus’s genetic material. By inhibiting this capsid, the drug prevents HIV from replicating inside human cells. Unlike daily oral PrEP options like Truvada or Descovy, Yeztugo is designed to overcome common adherence issues by requiring just one injection every six months. This simplifies prevention for at-risk populations, especially those who struggle with daily medication routines. While the approval is being hailed as a major victory in the global fight against HIV, access and affordability remain concerns. The U.S. list price for a year’s supply is expected to be around $28,000, though Gilead has committed to providing generics to 120 low-income countries and producing up to 10 million doses by 2026. Global health experts see this breakthrough as a turning point that could drastically reduce new HIV infections—if distribution is equitable and timely. In summary, Yeztugo's approval represents a critical milestone in HIV prevention science, combining exceptional efficacy, convenience, and innovation. It has the potential to reshape the future of HIV prevention—especially if healthcare systems can ensure widespread access to those most in need.
    Like
    Love
    Wow
    3
    · 0 Comments ·0 Shares ·40K Views
  • Indonesia’s Lewotobi Laki-Laki volcano, located on Flores Island, erupted twice in the span of two days—on June 17 and 18, 2025. The first eruption launched a massive ash plume nearly 11 kilometers (about 6.8 miles) into the sky, forming a dramatic mushroom-shaped cloud visible from up to 150 kilometers away.

    The second eruption followed with a slightly smaller ash column reaching 3–5 kilometers high. These eruptions prompted authorities to raise the volcano’s alert status to the highest level (Level 4), indicating significant risk to nearby populations.

    The eruptions forced the closure of Maumere Airport and disrupted dozens of international flights to and from Bali, affecting travelers from India, Singapore, Australia, and other countries.

    Officials extended the evacuation zone to an 8-kilometer radius around the volcano, urging residents of villages like Boru, Hewa, and Watobuku to leave the area. Ash and volcanic debris blanketed these communities, though fortunately no casualties have been reported so far.

    The Indonesian volcanology agency warned of further activity, especially given recent heavy rainfall, which raises the risk of secondary hazards such as lava flows or volcanic mudslides.

    Emergency teams continue to monitor the volcano closely, while local residents brace for possible aftershocks or additional eruptions in the coming days.
    Indonesia’s Lewotobi Laki-Laki volcano, located on Flores Island, erupted twice in the span of two days—on June 17 and 18, 2025. The first eruption launched a massive ash plume nearly 11 kilometers (about 6.8 miles) into the sky, forming a dramatic mushroom-shaped cloud visible from up to 150 kilometers away. The second eruption followed with a slightly smaller ash column reaching 3–5 kilometers high. These eruptions prompted authorities to raise the volcano’s alert status to the highest level (Level 4), indicating significant risk to nearby populations. The eruptions forced the closure of Maumere Airport and disrupted dozens of international flights to and from Bali, affecting travelers from India, Singapore, Australia, and other countries. Officials extended the evacuation zone to an 8-kilometer radius around the volcano, urging residents of villages like Boru, Hewa, and Watobuku to leave the area. Ash and volcanic debris blanketed these communities, though fortunately no casualties have been reported so far. The Indonesian volcanology agency warned of further activity, especially given recent heavy rainfall, which raises the risk of secondary hazards such as lava flows or volcanic mudslides. Emergency teams continue to monitor the volcano closely, while local residents brace for possible aftershocks or additional eruptions in the coming days.
    Like
    Love
    Wow
    3
    · 0 Comments ·0 Shares ·39K Views
  • June 2025 summer gaming festivals be like
    June 2025 summer gaming festivals be like
    Like
    Love
    Wow
    3
    · 0 Comments ·0 Shares ·38K Views
  • Juneteenth
    Juneteenth
    Like
    Love
    Wow
    3
    · 0 Comments ·0 Shares ·37K Views
More Results